Our fibronectin facilitates attachment and cytoplasmic spreading during cell and tissue culture for all types of anchorage-dependent cells. With the recent collaboration with Terumo Blood and Cell Technologies, our fibronectin integrates with the Quantum Flex™ Cell Expansion System. This integration paves the way for MSC-based therapy developers to leverage automation to scale reliably from research to clinical manufacturing. Our continued innovation with Terumo Blood and Cell Technologies ensures that you’re prepared for the future of MSC-based therapies.
*Sale ends September 30, 2026
Why use Akron’s cGMP Fibronectin?
|
![]() |
Manual cell expansion limits the potential of MSC-based therapies, as it requires significant hands-on time from highly trained users and involves many open steps, leading to variability. This creates challenges when scaling up for cell therapy manufacturing and presents the need for larger-scale automation solutions to allow for more industry growth.
Learn how Akron Bio and Terumo Blood and Cell Technologies are addressing the growing need for automation in the cell expansion space in the following study.
Disclaimer: Shipping and handling fees apply. Terms and conditions apply.